Saturday 17 October 2026
Export PAVM’s income statement to Excel — free account
PAVmed Inc.
PAVM Healthcare Medical Devices
PAVmed Inc.’s revenue for fiscal 2025 (year ended December 2025) was $71,000.00, down 97.6% from fiscal 2024. In the quarter to June 2026, revenue grew 450.0%, EPS grew 96.1% and free cash flow fell 125.6%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
2.41
0.02
−0.82%
Follow PAVM
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
1.00 | 0.91 | 0.00 | 0.00 |
P/S ratio |
320.04 | 62.61 | 188.77 | 332.50 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(10.36) | (2.87) | (6.12) | (13.98) | |
P/B ratio |
0.00 | 0.00 | 0.76 | 2.41 | |
Price to Tangible BV |
0.00 | 0.00 | 0.79 | 2.57 | |
EV/Sales |
328.32 | 88.03 | 288.06 | 433.54 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.67) | (1.20) | (3.92) | (6.28) | |
EV/FCF |
(2.95) | (1.28) | (4.12) | (6.53) | |
Quick Ratio |
0.30 | 0.10 | 1.77 | 0.93 | |
Current Ratio |
0.40 | 0.17 | 2.02 | 1.19 | |
Net Debt/EBITDA |
0.64 | 0.23 | (1.05) | (1.62) | |
Debt/Assets |
0.00% | 0.00% | 32.81% | 37.55% | |
Debt/Equity |
0.00 | 0.00 | 0.60 | 0.78 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.14 | 0.85 | 0.37 | 0.49 | |
Capex/Depreciation |
(0.14) | (0.78) | (1.10) | (0.68) | |
Interest Coverage |
(605.50) | (1,360.20) | (2,678.33) | (3,511.00) | |
Research and Development Expense of Revenue |
21,760.00% | 3,513.46% | 6,309.09% | 6,263.64% | |
Selling, General and Administrative Expense of Revenue |
74,120.00% | 9,500.00% | 29,872.73% | 14,745.45% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
7,660.00% | 446.15% | 827.27% | 2,778.79% | |
Graham Net Nets |
(1.22) | (3.14) | (0.81) | (0.43) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
100.04% | 109.83% | (368.48%) | (270.18%) | |
Free Cash Flow Yield |
(34.82%) | (109.93%) | (37.03%) | (19.96%) | |
Revenue per Share |
0.01 | 0.08 | 0.01 | 0.01 | |
Operating CF per Share |
(1.25) | (2.31) | (1.66) | (0.42) | |
Capex per Share |
0.00 | (0.02) | (0.01) | 0.00 | |
Free Cash Flow per Share |
(1.25) | (2.33) | (1.67) | (0.43) | |
Cash per Share |
4.32 | 2.29 | 4.09 | 0.60 | |
Shareholders Equity per Share |
31.38 | 33.26 | 15.81 | 3.08 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
31.38 | 33.26 | 15.81 | 3.08 | |
Free Cash Flow |
(0.90) | (1.56) | (2.64) | (2.68) | |
Working Capital |
(6.27) | (12.28) | 3.75 | 0.77 | |
Capital Expenditures |
0.00 | (0.01) | (0.02) | (0.01) | |
Net Current Asset Value |
(11.35) | (13.95) | (13.02) | (16.05) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.60 | 0.27 | 1.00 | 0.39 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.01 | 0.02 | 0.02 | 0.01 | |
Average Payables |
0.40 | 0.67 | 0.68 | 0.72 | |
Average Assets |
34.31 | 34.74 | 49.12 | 42.05 | |
Average Common Equity |
(7.08) | (6.36) | 16.94 | 9.52 |
Columns are period end dates